Mendus AB (publ)
Mendus AB (publ), a biopharmaceutical company, develops immunotherapies for the treatment of tumor recurrence and established tumors. Its lead product is vididencel (DCP-001), which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia (AML); Phase II CADENCE clinical trial to treat AML; and Phase I ALISON clinical trial for the treatment of ovarian cancers. The com… Read more
Mendus AB (publ) - Asset Resilience Ratio
Mendus AB (publ) (IMMU) has an Asset Resilience Ratio of 10.29% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2025)
This chart shows how Mendus AB (publ)'s Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Mendus AB (publ)'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr64.66 Million | 10.29% |
| Short-term Investments | Skr0.00 | 0% |
| Total Liquid Assets | Skr64.66 Million | 10.29% |
Asset Resilience Insights
- Moderate Liquidity: Mendus AB (publ) has 10.29% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Mendus AB (publ) Industry Peers by Asset Resilience Ratio
Compare Mendus AB (publ)'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Mendus AB (publ) (2014–2025)
The table below shows the annual Asset Resilience Ratio data for Mendus AB (publ).
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 10.29% | Skr64.66 Million | Skr628.32 Million | -4.34pp |
| 2024-12-31 | 14.63% | Skr101.91 Million | Skr696.36 Million | -1.34pp |
| 2023-12-31 | 15.98% | Skr120.78 Million | Skr755.95 Million | +9.23pp |
| 2022-12-31 | 6.75% | Skr41.85 Million | Skr620.39 Million | -14.80pp |
| 2021-12-31 | 21.54% | Skr155.31 Million | Skr720.98 Million | -1.47pp |
| 2020-12-31 | 23.01% | Skr167.64 Million | Skr728.66 Million | +18.53pp |
| 2019-12-31 | 4.47% | Skr13.59 Million | Skr303.83 Million | -94.27pp |
| 2018-12-31 | 98.74% | Skr444.70 Million | Skr450.37 Million | +46.61pp |
| 2017-12-31 | 52.13% | Skr128.32 Million | Skr246.15 Million | +44.29pp |
| 2016-12-31 | 7.84% | Skr9.53 Million | Skr121.57 Million | +1.68pp |
| 2015-12-31 | 6.15% | Skr9.49 Million | Skr154.24 Million | -43.72pp |
| 2014-12-31 | 49.87% | Skr35.43 Million | Skr71.03 Million | -- |